THYROID EYE DISEASE
Clinical trials for THYROID EYE DISEASE explained in plain language.
Never miss a new study
Get alerted when new THYROID EYE DISEASE trials appear
Sign up with your email to follow new studies for THYROID EYE DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could fewer infusions be enough for thyroid eye disease?
Disease control Not yet recruitingThis study compares a shortened 4-infusion course of the drug Teprotumumab (Tepezza) to the standard 8-infusion course in people with active thyroid eye disease. It aims to see if those who respond well early can safely stop treatment sooner. About 40 participants who show early …
Matched conditions: THYROID EYE DISEASE
Phase: PHASE4 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
Second chance for thyroid eye disease patients: new drug trial targets Non-Responders
Disease control Not yet recruitingThis study tests a drug called AMG 732 in people with thyroid eye disease who did not respond to treatment or whose symptoms returned after a previous study. About 30 adults will receive the drug to see if it reduces eye bulging. The goal is to find a better option for those who …
Matched conditions: THYROID EYE DISEASE
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug aims to reduce bulging eyes in thyroid disease
Disease control Not yet recruitingThis study tests a new drug called teprotumumab N01 against standard steroid treatment for active thyroid eye disease, which causes eye bulging and discomfort. About 92 adults with moderate-to-severe symptoms will be randomly assigned to one of the two treatments. The main goal i…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE4 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New hope for bulging eyes: drug trial targets thyroid eye disease
Disease control Not yet recruitingThis study tests a new drug called NTB003 for people with thyroid eye disease, a condition that can cause bulging eyes and discomfort. About 74 adults aged 18 to 75 with active disease will receive the drug to see if it safely reduces eye bulging and inflammation. The goal is to …
Matched conditions: THYROID EYE DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated May 01, 2026 16:00 UTC